Business Wire

Vista Group, Global Leader in Film Industry Software, Unveils Latest Innovations at CineEurope 2018

Jaa

Vista Group International (NZX & ASX: VGL), the world’s leading provider of software solutions for the film industry, will be showcasing a host of innovations and thought leaders at CineEurope 2018 from June 11-14 in Barcelona, Spain.

Cinema Manager is Vista Cinema’s first major software release toward making our cinema management suite of products cloud-ready. See for yourself at Booth #101 why Cinema Manager has received stunning feedback on its new intuitive user interface which enables a cinema manager’s common tasks to be completed in less time and with fewer risk of errors.

From the Vista Apps portfolio, enhancements to Vista Mobile enable moviegoers to satisfy their F&B cravings without leaving the auditorium. Leveraging Vista’s moviegoer app (Mobile), and staff app (InTouch), new functionality creates an integrated workflow between the two. Guests request assistance from their seat with Vista Mobile, and staff responds with InTouch to resolve their enquiries.

Cinema Intelligence , the leader in business intelligence solutions, comes to CinemaCon with three major advances. Film Manager (FM), in collaboration with Vista Cinema, provides customers with optimized booking, scheduling and analytics capabilities. Advanced Booking optimizes the booking and content planning process with an advanced and intelligent tool that empowers cinema exhibitors to make the best decisions based on past performance, forecasting information and “what-if” analysis. Opus Data integration allows customers to access domestic Box Office performance directly in Cinema Intelligence, removing the need to chase information on multiple industry specific sites.

Veezi , Vista’s cloud-based cinema management solution for independent cinemas, which will exhibit at Booth #107, continues its extraordinary march across the U.S. independents sector and in Europe has secured customers in Spain, France, Sweden and Finland.

MovieXchange (MX) is Vista Group’s new web platform designed to streamline historically disparate and inefficient movie industry processes. Via MX products MX Film, MX Showtimes and MX Tickets, the product enables the sharing of distributor-supplied promotional movie materials essential to exhibitors, the central availability of global (and marketable) cinema show-time data, and a single source that ticket sellers can connect to and transact against all exhibitors. Additional to the accrued benefits to distributors, exhibitors and ticketing vendors, movieXchange enables a range of streamlined options for moviegoers to choose their movie and book their seat. Tickets are selling fast and volumes increasing weekly via the movieXchange platform.

Powster will be showcasing three new product innovations in the main foyer (CI Booth 26). After successful Beta testing, Powster Full Ticketing is live. The Powster ticketing model, in part related to movieXchange’s MX Ticket Service (Vista’s new global ticketing platform), is unique to the industry. Payments are deposited directly to the cinema's merchant account, eliminating previous administrative hang-ups. For studios, Powster full ticketing ensures visibility and measurement of the entire purchasing process culminating in actual ticket sales and helping the studio to sell more tickets at the cinema.

Facebook research shows 50% of group conversations on Messenger talk about movies. Powster’s Movies on Messenger allows cinemagoers to purchase movie tickets and organize groups of friends directly within Facebook Messenger. Augmented reality movie posters will be showcased on the Powster screen using Warner Brothers’ The Meg and Paramount’s Mission Impossible: Fallout as demonstrations. Moviegoers can now scan posters to see showtimes, watch the trailer, or interact with a custom-built AR experience.

Vista Group Panelists:

Mischa Kay, Vista Entertainment Solutions (‘Vista Cinema’) Managing Director, EMEA, will participate in the panel: “Software Analytics & Digital Marketing in Cinema” on Tuesday, June 12th from 11:30am to 1:30pm. (Exhibition Hall, Level 0)

Gabriel Swartland, Head of Client Services, EMEA, for Movio, will be a panelist for “Jump-Starting Event Cinema” Thursday, June 14th at 1:45pm to 2:45pm. (Exhibition Hall, Level 0)

Visit Vista at:
Vista Group Booth 101
Veezi Booth 107
Powster in CI Booth 206

About Vista Group International:

Vista Group International (Vista Group) is a public company, listed on both the New Zealand and Australian stock exchanges (NZX & ASX: VGL). The Group provides software and additional technology solutions across the global film industry. Cinema management software is provided by Vista Entertainment Solutions (‘Vista Cinema’), the core business of the Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based SaaS software for the Independent Cinema Market), movieXchange (connecting the movie industry to simplify the promotion and sale of movie tickets), Maccs (film distribution software), Numero (box office reporting software for film distributors and cinemas), Cinema Intelligence (business intelligence solutions), Powster (creative studio and marketing platform for movie studios) and Flicks (moviegoer ‘go to’ portal for movie information) provide an innovative range of complementary products across additional film industry sectors, from production and distribution, to cinema exhibition through to the moviegoer experience. Vista Group has offices located in New Zealand (Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn: www.linkedin.com/company/vista-group-limited

Contact information

Press Contacts:
Maggie Begley/MBC
(O) 310.390.0101
(M) 310.749.3055
Maggie@mbcprinc.com
or
Vista Group International/Auckland, NZ
Christine Fenby
christine.fenby@vista.co; +64 21 727 006

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme